Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 9/20 | 0.67 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.64 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14489882 | 0.95 | EGFR (0.68) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL29623531 | 0.93 | EGFR (0.68) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL186199 | 0.93 | EGFR (0.68) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL12536476 | 0.93 | EGFR (0.68) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL14489878 | 0.92 | EGFR (0.69) | EGFRERBB2 | |
| SCHEMBL1446265 | 0.92 | EGFR (0.68) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL12743515 | 0.92 | EGFR (0.68) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL14489874 | 0.91 | EGFR (0.80) | EGFRERBB2 | |
| SCHEMBL175261 | 0.91 | EGFR (0.66) | EGFRERBB2HDAC3HDAC4HDAC1 | |
| SCHEMBL29623541 | 0.91 | EGFR (0.66) | EGFRERBB2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007068552-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF, AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | HIMMELSBACH FRANK | 2007-06-14 | — | — | US | disclosed |
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | HIMMELSBACH FRANK | 2007-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135463-A1 | Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing same | BPHL, CYP11B2, CYP11B1 | EGFR 349/4885ERBB2 83/4885HDAC3 2498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.